title: Qualitative analysis of hippocampal plastic changes in rats with epilepsy supplemented with oral omega-3 fatty acids.
abstract: Studies have provided evidence of the important effects of omega-3 fatty acid on the brain in neurological conditions, including epilepsy. Previous data have indicated that omega-3 fatty acids lead to prevention of status epilepticus-associated neuropathological changes in the hippocampal formation of rats with epilepsy. Omega-3 fatty acid supplementation has resulted in extensive preservation of GABAergic cells in animals with epilepsy. This study investigated the interplay of these effects with neurogenesis and brain-derived neurotrophic factor (BDNF). The results clearly showed a positive effect of long-term omega-3 fatty acid supplementation on brain plasticity in animals with epilepsy. Enhanced hippocampal neurogenesis and BDNF levels and preservation of interneurons expressing parvalbumin were observed. Parvalbumin-positive cells were identified as surviving instead of newly formed cells. Additional investigations are needed to determine the electrophysiological properties of the newly formed cells and to clarify whether the effects of omega-3 fatty acids on brain plasticity are accompanied by functional gain in animals with epilepsy.
authors.affiliation: Programa de Pós-graduação em Distúrbios do Desenvolvimento da Universidade Presbiteriana Mackenzie, São Paulo, SP, Brazil.
authors.forename: Roberta M
authors.initials: RM
authors.lastname: Cysneiros
authors.forename: Danuza
authors.initials: D
authors.lastname: Ferrari
authors.forename: Ricardo M
authors.initials: RM
authors.lastname: Arida
authors.forename: Vera C
authors.initials: VC
authors.lastname: Terra
authors.forename: Antonio-Carlos G
authors.initials: AC
authors.lastname: de Almeida
authors.forename: Esper A
authors.initials: EA
authors.lastname: Cavalheiro
authors.forename: Fulvio A
authors.initials: FA
authors.lastname: Scorza
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D001973:Bromodeoxyuridine / Q000378:metabolism; D003975:Diazepam / Q000627:therapeutic use; D004195:Disease Models, Animal; D004827:Epilepsy / Q000139:chemically induced / Q000178:diet therapy* / Q000473:pathology*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D009473:Neuronal Plasticity / Q000187:drug effects*; D010320:Parvalbumins / Q000378:metabolism; D010862:Pilocarpine; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000927:Anticonvulsants; D019208:Brain-Derived Neurotrophic Factor; D015525:Fatty Acids, Omega-3; C489787:MAP2 protein, rat; D008869:Microtubule-Associated Proteins; D010320:Parvalbumins; D010862:Pilocarpine; D001973:Bromodeoxyuridine; D003975:Diazepam